GMAB Genmab A/S
$44.67▼ -0.03%
Healthcare
Other
After hours
$44.67▲ +0.00%
Oct 27, 4:53 PM ET
Volume 4.93M
Avg Volume (10D) 4.99M
Key Metrics & Fundamentals
Market Cap
$27.47B
P/E Ratio
34.6
Div Yield
0.00%
52W Range
23.62 - 45.45
% vs 50 MA
25.09%
% vs 200 MA
48.08%
RSI-14
79.5
MACD Histogram
+0.7000
Beta (1Y vs SPY)
0.86
Free Cash Flow
$48.00M
Gross Rev
$1.16B
Gross Profit
$1.07B
EBITDA
$469.00M
COGS
$84.00M
Operating Exp
$664.00M
Operating Income
$407.00M
EBIT
$407.00M
Pretax Income
$295.00M
Net Income
$303.00M
EPS (Diluted)
0.49
Price & Volume History
Loading chart…
Recent News
J.P. Morgan upgrades Genmab on cancer drug growth potential
Investing.com · Oct 27, 2026 7:11 AM ET
Petosemtamab Trial Results May Change The Case For Genmab Stock
Simply Wall St. · Oct 26, 2026 7:23 PM ET
Health Care Roundup: Market Talk
The Wall Street Journal · Oct 26, 2026 5:07 PM ET
European stocks rebound as corporate optimism lifts mood ahead of rate decisions
Reuters · Oct 26, 2026 1:37 PM ET
Genmab's Encouraging Oncology Data Boosts Investor Optimism
Benzinga · Oct 26, 2026 11:08 AM ET
Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy
Zacks · Oct 26, 2026 10:25 AM ET
Genmab Reports 28.2-Month Median Survival in Petosemtamab Combination Trial
MT Newswires · Oct 26, 2026 7:53 AM ET
Genmab Shares Jump After Positive Cancer Study Results
The Wall Street Journal · Oct 26, 2026 7:46 AM ET
Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
GlobeNewswire · Oct 26, 2026 7:00 AM ET
Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Business Wire · Oct 26, 2026 7:00 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See GMAB's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.